CCL

Összesen 4 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM067990
Első szerző:Brodszky Valentin
Cím:Determinants of biological drug survival in rheumatoid arthritis : evidence from a Hungarian rheumatology center over 8 years of retrospective data / Brodszky Valentin, Bíró Anikó, Szekanecz Zoltán, Soós Boglárka, Baji Petra, Rencz Fanni, Tóthfalusi László, Gulácsi László, Péntek Márta
Dátum:2017
Megjegyzések:Objective: To compare drug survival of biological therapies in patients with rheumatoid arthritis (RA), and analyze the determinants of discontinuation probabilities and switches to other biological therapies.Materials and methods: Consecutive RA patients initiating first biological treatment in one rheumatology center between 2006 and 2013 were included. Log-rank test was used to analyze the differences between the survival curves of different biological drugs. Cox regression was applied to analyze the discontinuation due to inefficacy, the occurrence of adverse events, or to any reasons.Results: A total of 540 patients were included in the analysis. The most frequently used first-line biological treatments were infliximab (N=176, 33%), adalimumab (N=150, 28%), and etanercept (N=132, 24%). Discontinuation of first tumor necrosis factor-alpha (TNF-?) treatment was observed for 347 (64%) patients, due to inefficacy (n=209, 60%), adverse events (n=103, 30%), and other reasons (n=35, 10%). Drug survival rates for TNF-? and non-TNF-? therapies were significantly different, and were in favor of non-TNF-? therapies. Every additional number of treatment significantly increased the risk of inefficacy by 27% (p<0.001) and of adverse events by 35% (p=0.002). After the discontinuation of the initial TNF-? treatment, switching to rituximab and tocilizumab was associated with significantly longer treatment duration than switching to a second TNF-?. The non-TNF-? therapies resulted in significantly longer treatment duration,due to both less adverse events and longer maintenance of effectiveness.Conclusion: Non-TNF-? therapies resulted in significantly longer treatment duration, and lost their effectiveness later. Increase in the number of switches significantly increased the risk of discontinuation of any biological therapy.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:ClinicoEconomics and outcomes research 9 (2017), p. 139-147. -
További szerzők:Bíró Anikó Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Soós Boglárka (1988-) (általános orvos) Baji Petra Rencz Fanni Tóthfalusi László Gulácsi László Péntek Márta
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM076714
Első szerző:Gulácsi László
Cím:Long-Term Efficacy of Tumor Necrosis Factor Inhibitors for the Treatment of Methotrexate-Naïve Rheumatoid Arthritis : systematic Literature Review and Meta-Analysis / László Gulácsi, Zsombor Zrubka, Valentin Brodszky, Fanni Rencz, Rieke Alten, Zoltán Szekanecz, Márta Péntek
Dátum:2019
ISSN:0741-238X
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Advances In Therapy. - 36 : 3 (2019), p. 721-745. -
További szerzők:Zrubka Zsombor Brodszky Valentin Rencz Fanni Alten, Rieke Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Péntek Márta
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

3.

001-es BibID:BIBFORM063074
035-os BibID:(WOS)000375091500029 (Scopus)84959432278
Első szerző:Gulácsi László
Cím:Patients' access to biological therapy in chronic inflammatory conditions : per capita GDP does not explain the intercountry differences / László Gulácsi, Fanni Rencz, Gyula Poór, Zoltán Szekanecz, Valentin Brodszky, Petra Baji, Márta Péntek
Dátum:2016
ISSN:0003-4967
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Annals Of The Rheumatic Diseases. - 75 (2016), p. 942-943. -
További szerzők:Rencz Fanni Poór Gyula Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Brodszky Valentin Baji Petra Péntek Márta
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

4.

001-es BibID:BIBFORM081584
Első szerző:Zrubka Zsombor
Cím:Long-term efficacy and cost-effectiveness of infliximab as first-line treatment in rheumatoid arthritis : systematic review and meta-analysis / Zrubka Zsombor, Gulácsi László, Brodszky Valentin, Rencz Fanni, Alten Rieke, Szekanecz Zoltán, Péntek Márta
Dátum:2019
ISSN:1473-7167 1744-8379
Megjegyzések:Introduction: Early biological treatment of rheumatoid arthritis (RA) may reverse the autoimmune response in some patients resulting in favorable long-term outcomes. Although the cost-effectiveness of this strategy has been questioned, biosimilar entries warrant the revision of clinical and pharmaco-economic evidence. Areas covered: We conducted a systematic review of randomized controlled trials (RCTs) published up to 24 May 2018 in Pubmed, EMBASE and Cochrane CENTRAL, comparing infliximab with non-biological therapy in patients with RA naïve to methotrexate. We performed meta-analyses for efficacy outcomes at month 6 and years 1 and 2. Six RCTs were identified, involving 1832 patients. At month 6 ACR70 response and remission, and at year 1 ACR20/ACR70 responses and remission were improved significantly with first-line infliximab versus control. The differences were not significant at year 2. We reviewed cost-utility studies, up to 31 October 2018 in PubMed, Cochrane CENTRAL and the CRD HTA databases. Four studies indicated that first-line use of originator infliximab calculated at 2005?2008 prices was not cost-effective. Expert opinion: We demonstrated the efficacy benefits of first-line infliximab therapy up to 1 year in methotrexate-naïve RA. We highlighted the need for standardized reporting of outcomes and conducting cost-effectiveness analyses of first-line biosimilar therapy in RA.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Biosimilar
cost-utility analysis
efficacy
infliximab
meta-analysis
early rheumatoid arthritis
Megjelenés:Expert Review of Pharmacoeconomics & Outcomes Research. - 19 : 5 (2019), p. 537-549. -
További szerzők:Gulácsi László Brodszky Valentin Rencz Fanni Alten, Rieke Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Péntek Márta
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1